Plain-English translation of NCT07730788 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing how well nemolizumab works for moderate-to-severe eczema by using a special imaging camera called reflectance confocal microscopy. This camera takes detailed pictures of your skin at the cellular level — something that regular skin exams cannot do. The study wants to see what changes happen in your skin when you receive this medication.
Right now, doctors can only measure eczema improvement using standard rating scales that rely on what they see with their eyes, and these can vary between different doctors. This study hopes to find a more precise, objective way to track whether this medication is actually healing the deeper layers of your skin — which could lead to better ways of measuring treatment success in the future.
You likely qualify if…
You likely don't qualify if…
You will receive the medication nemolizumab as prescribed by your doctor for your eczema treatment. At specific visits, a researcher will use a reflectance confocal microscope — a noninvasive imaging device that takes detailed pictures of your skin without any needles or cuts — to examine the skin on your affected areas. The study will track these images over time to see how the treatment changes your skin's structure and inflammation at the cellular level.
AI-generated summary from trial data · Aug 7, 2026 · Not medical advice
France